Erratum to "In vivo animal models for drug delivery across the lung mucosal barrier"[Advanced Drug Delivery Reviews 59 (2007) 1133-1151] (DOI:10.1016/j.addr.2007.08.023);In vivo animal models for drug delivery across the lung mucosal barrier

Advanced Drug Delivery Reviews

Volumn 59, Issue 11, 2007, Pages 1133-1151

  Cryan, Sally Ann ^a   Sivadas, Neeraj ^a   Garcia Contreras, Lucila ^b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Aerosol; Drug absorption; Drug deposition; Inhalation; Pharmacokinetics; Respiratory delivery; Systemic drug delivery; Toxicity

Indexed keywords

ABSORPTION; AEROSOLS; BIOLOGICAL ORGANS; DRUG PRODUCTS; PHARMACOKINETICS; TOXICITY;

DRUG ABSORPTION; DRUG DEPOSITION; RESPIRATORY DELIVERY; SYSTEMIC DRUG DELIVERY;

DRUG DELIVERY;

ADRENALIN; AMIKACIN; AMPHOTERICIN B; ANTIBIOTIC AGENT; APOMORPHINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA INTERFERON; BLOOD CLOTTING FACTOR 9; CALCITONIN; CETRORELIX; CYCLOSPORIN; DRONABINOL; FENTANYL; FOLLITROPIN; GLUCAGON LIKE PEPTIDE 1; GLYCERYL TRINITRATE; HEPARIN; ILOPROST; IMMUNOGLOBULIN; INSULIN; ISONIAZID; LUTEINIZING HORMONE DERIVATIVE; PARATHYROID HORMONE; PROCHLORPERAZINE; RHESUS ANTIBODY; RIBAVIRIN; STEROID; SUMATRIPTAN; UNIPROST;

AEROSOL; BIOLOGICAL MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA; REVIEW; SIMULATION;

EID: 35448952967     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.11.002     Document Type: Erratum

References (216)

1. Colthorpe P. Industry experiences of the HFA transition. Drug. Deliv. Syst. Sci. 32 (2003) 41
2. Gonda I. The ascent of pulmonary drug delivery. J. Pharm. Sci. 897 (2000) 940-945
3. Sanjar S., and Matthews J. Treating systemic diseases via the lung. J. Aerosol Med. 14 Suppl 1 (2001) S51-S58
4. Schanker L.S. Drug absorption from the lung. Biochem. Pharmacol. 274 (1978) 381-385
5. Patton J.S., Fishburn C.S., and Weers J.G. The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc. 14 (2004) 338-344
6. Patton J.S. Mechanisms of macromolecule absorption by the lungs. Adv. Drug Deliv. Rev. 19 (1996) 3-36
7. Patton J.S., Nagarajan S., and Clark A. Pulmonary absorption and metabolism of peptides and proteins. In: Dalby R., Byron P., and Farr S. (Eds). Respiratory Drug Delivery vol. VI (1998), Interpharm Press, Buffalo Grove 17-24
8. In: Weibel E. (Ed). Morphometry of the Human Lung (1963), Academic, New York
9. Kim K.-J., Borok Z., and Crandall E.D. A useful in vitro model for transport studies of alveolar epithelial barrier. Pharm. Res. 183 (2001) 253-255
10. Florea B.I., Cassara M.L., Junginger H.E., and Borchard G. Drug transport and metabolism characteristics of the human airway epithelial cell line Calu-3. J. Control. Release 87 (2003) 131-138
11. Gumbleton M., Hollins A.J., Omidi Y., Campbell L., and Taylor G. Targeting caveolae for vesicular drug transport. J. Control. Release 871-873 (2003) 139-151
12. Kim K.-J., and Malik A.B. Protein transport across the lung epithelial barrier. Am. J. Physiol. 2842 Pt. 1 (2003) L247-L259
13. Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc. Am. Thorac. Soc. 14 (2004) 315-320
14. Gonda I. Systemic delivery of drugs to humans via inhalation. J. Aerosol Med. 191 (2006) 47-53
15. Newman S.P., Steed K.P., Reader S.J., Hooper G., and Zierenberg B. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J. Pharm. Sci. 859 (1996) 960-964
16. Schuster J., Rubsamen R., Lloyd P., and Lloyd J. The AERX aerosol delivery system. Pharm. Res. 143 (1997) 354-357
17. Perera A.D., Kapitza C., Nosek L., Fishman R.S., Shapiro D.A., Heise T., and Heinemann L. Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes. Diabetes Care 2512 (2002) 2276-2281
18. White S., Bennett D.B., Cheu S., Conley P.W., Guzek D.B., Gray S., Howard J., Malcolmson R., Parker J.M., Roberts P., Sadrzadeh N., Schumacher J.D., Seshadri S., Sluggett G.W., Stevenson C.L., and Harper N.J. EXUBERA: pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol. Ther. 76 (2005) 896-906
19. Edwards D.A., and Dunbar C. Bioengineering of therapeutic aerosols. Annu. Rev. Biomed. Eng. 4 (2002) 93-107
20. Schneeberger E.E. Structural basis for some permeability properties of the air-blood barrier. Fed. Proc. 3711 (1978) 2471-2478
21. Sayani A.P., and Chien Y.W. Systemic delivery of peptides and proteins across absorptive mucosae. Crit. Rev. Ther. Drug Carr. Syst. 131-132 (1996) 85-184
22. Hogg J.C. Response of the lung to inhaled particles. Med. J. Aust. 14213 (1985) 675-678
23. Lombry C., Edwards D.A., Preat V., and Vanbever R. Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. Am. J. Physiol., Lung Cell. Mol. Physiol. 2865 (2004) L1002-L1008
24. Oberdorster G., Cox C., and Gelein R. Intratracheal instillation versus intratracheal-inhalation of tracer particles for measuring lung clearance function. Exp. Lung Res. 231 (1997) 17-34
25. Zhang J.Y., Wang Y., and Prakash C. Xenobiotic-metabolizing enzymes in human lung. Curr. Drug Metab. 78 (2006) 939-948
26. Sakagami M. Insulin disposition in the lung following oral inhalation in humans: a meta-analysis of its pharmacokinetics. Clin. Pharmacokinet. 438 (2004) 539-552
27. Patton J.S., and Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug. Discov. 61 (2007) 67-74
28. Davis S. Delivery of peptide and non-peptide drugs through the respiratory tract. PSTT 2 2 (1999) 450-456
29. Scheuch G., Kohlhaeufl M.J., Brand P., and Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv. Drug Deliv. Rev. 589-610 (2006) 996-1008
30. Shoyele S.A., and Slowey A. Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery. Int. J. Pharm. 3141 (2006) 1-8
31. Kobayashi S., Kondo S., and Juni K. Critical factors on pulmonary absorption of peptides and proteins: diffusional barrier and metabolic barrier. Eur. J. Pharm. Sci. 4 (1996) 367-372
32. Patton J.S., Nagarajan S., and Clark A. Pulmonary absorption and metabolism of peptides and proteins. In: Dalby R., Byron P., and Farr S. (Eds). Respiratory Drug Delivery (1996), Interpharm Press, Buffalo Grove 17-24
33. Byron P.R. Determinants of drug and polypeptide bio-availability from aerosols delivered to the lungs. Adv. Drug Deliv. Rev. 5 (1990) 107-132
34. Hochrainer D., Holz H., Kreher C., Scaffidi L., Spallek M., and Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J. Aerosol Med. 183 (2005) 273-282
35. Wollmer P., Pieber T.R., Gall M.A., and Brunton S. Delivering needle-free insulin using AERx iDMS (insulin diabetes management system) technology. Diabetes Technol. Ther. 9 Suppl 1 (2007) S57-S64
36. Rave K., Nosek L., Heinemann L., Gonzales C., Ernest C.S., Chien J., and Muchmore D. Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles. Diabet. Med. 217 (2004) 763-768
37. Adjei L., and Gupta P. Inhalation delivery of therapeutic peptides and proteins. In: Lenfant C. (Ed). Lung Biology in Health and Disease (1997), Marcel Dekker, New York 1-913
38. Niven R.W., Whitcomb K.L., Shaner L., Ip A.Y., and Kinstler O.B. The pulmonary absorption of aerosolized and intratracheally instilled rhG-CSF and monoPEGylated rhG-CSF. Pharm. Res. 129 (1995) 1343-1349
39. Kobayashi S., Kondo S., and Juni K. Study on pulmonary delivery of salmon calcitonin in rats: effects of protease inhibitors and absorption enhancers. Pharm. Res. 11 (1994) 1239-1243
40. Shao Z., Li Y., Chermak T., and Mitra A.K. Cyclodextrins as mucosal absorption promoters of insulin. II. Effects of beta-cyclodextrin derivatives on alpha-chymotryptic degradation and enteral absorption of insulin in rats. Pharm. Res. 118 (1994) 1174-1179
41. Yamamoto A., Okumura S., Fukuda Y., Fukui M., Takahashi K., and Muranishi S. Improvement of the pulmonary absorption of (Asu1,7)-eel calcitonin by various absorption enhancers and their pulmonary toxicity in rats. J. Pharm. Sci. 8610 (1997) 1144-1147
42. Suarez S., Garcia-Contreras L., Sarubbi D., Flanders E., O'Toole D., Smart J., and Hickey A.J. Facilitation of pulmonary insulin absorption by H-MAP: pharmacokinetics and pharmacodynamics in rats. Pharm. Res. 1812 (2001) 1677-1684
43. Bitonti A.J., Dumont J.A., Low S.C., Peters R.T., Kropp K.E., Palombella V.J., Stattel J.M., Lu Y., Tan C.A., Song J.J., Garcia A.M., Simister N.E., Spiekermann G.M., Lencer W.I., and Blumberg R.S. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc. Natl. Acad. Sci. U. S. A. 10126 (2004) 9763-9768
44. Cryan S.A. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J. 71 (2005) E20-E41
45. Liu F.Y., Shao Z., Kildsig D.O., and Mitra A.K. Pulmonary delivery of free and liposomal insulin. Pharm. Res. 102 (1993) 228-232
46. Li Y., and Mitra A.K. Effects of phospholipid chain length, concentration, charge, and vesicle size on pulmonary insulin absorption. Pharm. Res. 131 (1996) 76-79
47. Edwards D.A., Hanes J., Caponetti G., Hrkach J., Ben-Jebria A., Eskew M.L., Mintzes J., Deaver D., Lotan N., and Langer R. Large porous particles for pulmonary drug delivery. Science 2765320 (1997) 1868-1871
48. Kawashima Y., Yamamoto H., Takeuchi H., Fujioka S., and Hino T. Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J. Control. Release 621-622 (1999) 279-287
49. Pfutzner A., Mann A.E., and Steiner S.S. Technosphere/Insulin-a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol. Ther. 45 (2002) 589-594
50. Agu R.U., Ugwoke M.I., Armand M., Kinget R., and Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 24 (2001) 198-209
51. Sakagami M., Kinoshita W., Sakon K., Sato J., and Makino Y. Mucoadhesive beclomethasone microspheres for powder inhalation: their pharmacokinetics and pharmacodynamics evaluation. J. Control Release. 801-803 (2002) 207-218
52. Forbes B., and Ehrhardt C. Human respiratory epithelial cell culture for drug delivery applications. Eur. J. Pharm. Biopharm. 602 (2005) 193-205
53. Sakagami M., Byron P.R., Venitz J., and Rypacek F. Solute disposition in the rat lung in vivo and in vitro: determining regional absorption kinetics in the presence of mucociliary escalator. J. Pharm. Sci. 912 (2002) 594-604
54. Pang Y., Sakagami M., and Byron P.R. The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: implications of metabolism and regional deposition. Eur. J. Pharm. Sci. 254-255 (2005) 369-378
55. Sakagami M. in vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv. Drug Deliv. Rev. 58 (2006) 1030-1060
56. In: Wagner J.E., and Manning P.J. (Eds). The Biology of the Guinea Pig (1976), Academic Press, Inc., New York, NY
57. Lechner A.J., and Banchero N. Advanced pulmonary development in newborn guinea pigs (Cavia porcellus). Am. J. Anat. 163 (1982) 235-246
58. McMurray D.N. Guinea pig model of tuberculosis. In: Bloom B. (Ed). Tuberculosis: Pathogenesis, Protection, and Control (1994), ASM Press, Washington DC 135-148
59. Kuraki T., Ishibashi M., Takayama M., Shiraishi M., and Yoshida M. A novel oral neutrophia elastase inhibitor (ONO-6818) inhibits human neutrophil elastase-induced emphysema in rats. Am. J. Respir. Crit. Care Med. 166 (2002) 496-500
60. Huang J., Garmise R., Crowder T., Mar K., Hwang C., Hickey A., Mikszta J., and Sullivan V. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine 23 (2003) 794-801
61. Spond J., Case N., Chapman R.W., Crawley Y., Egan R.W., Fine J., Hey J.A., Kreutner W., Kung T., Wang P., and Minnicozzi M. Inhibition of experimental acute pulmonary inflammation by pirfenidone. Pulm. Pharmacol. Ther. 16 (2003) 207-214
62. Wohaieb S.A., and Godin D.V. Alterations in free radical tissue-defense mechanisms in streptozocin-induced diabetes in rat. Effects of insulin treatment. Diabetes 369 (1987) 1014-1018
63. Desigaux L., Gourden C., Bello-Roufaï M., Richard P., Oudrhiri N., Lehn P., Escande D., Pollard H., and Pitard B. Nonionic amphiphilic block copolymers promote gene transfer to the lung. Hum. Gene Ther. 16 (2005) 821-829
64. Gagnadoux F., Pape A., Lemarie E., Lerondel S., Valo I., Leblond V., Racineux J.-L., and Urban T. Aerosol delivery of chemotherapy in an orthotopic model of lung cancer. Eur. Respir. J. 26 (2005) 657-661
65. Surendrakumar K., Martyn G.P., Hodgers E.C.M., Jansen M., and Blair J.A. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J. Control. Release 91 (2003) 385-394
66. Skorohod N., and Yeates D. Superoxide dismutase failed to attenuate allergen-induced nasal congestion in ragweed-sensitized dogs. J. Appl. Physiol. 98 (2004) 1478-1486
67. Grainger C.I., Alcock R., Gard T.G., Quirk A.V., van Amerongen G., de Swart R.L., and Hardy J.G. Administration of an insulin powder to the lungs of cynolologus monkeys using a Penn Century insufflator. Int. J. Pharm. 269 (2003) 523-527
68. Beck S.E., Laube B.L., Barberena C.I., Fischer A.C., Adams R.J., Chesnut K., Flotte T.R., and Guggino W.B. Deposition and expression of aerosolized rAAV vectors in the lungs of Rhesus macaques. Mol. Ther. 6 (2002) 546-554
69. Murakami K., Bjertnaes L., Schmalstieg F., McGuire R., Cox R., Hawkins H., Herndon D., Traber L., and Traber D. A novel animal model of sepsis after acute lung injury in sheep. Crit. Care Med. 30 9 (2002) 2083-2090
70. Phalen R.F., and Oldham M.J. Airway structures: tracheobronchial airway structure as revealed by casting techniques. Am. Rev. Respir. Dis. 1282 (1983) s1-s4
71. Tyler W.S. Small airways and terminal units: comparative subgross anatomy of lungs. Am. Rev. Respir. Dis. 1282 (1983) s32-s36
72. Spektor D., Hunt P., Rosenthal F., and Lippmann M. Influence of airway and airspace sizes on particle deposition in excised donkey lungs. Exp. Lung Res. 93-94 (1985) 363-387
73. Esch J., Spektor D., and Lippmann M. Effect of lung airway branching pattern and gas composition on particle deposition. II. Experimental studies in human and canine lungs. Exp. Lung Res. 143 (1988) 321-348
74. Yeh H., Phalen R., and Raabe O. Factors influencing the deposition of inhaled particles. Environ. Health Perspect. 15 (1976) 147-156
75. Lippmann M., and Schlesinger R.B. Interspecies comparisons of particle deposition and mucociliary clearance in tracheobronchial airways. J. Toxicol. Environ. Health 132-133 (1984) 441-469
76. Crapo J.D., Young S.L., Fram E.K., Pinkerton K.E., Barry B.E., and Crapo R.O. Morphometric characteristics of cells in the alveolar region of mammalian lungs. Am. Rev. Respir. Dis. 1282 (1983) s43-s46
77. Matulionis D.H. Effects of cigarette smoke generated by different smoking machines on pulmonary macrophages of mice and rats. J. Anal. Toxicol. 84 (1984) 187-191
78. Oosting R.S., van Golde L.M., Verhoef J., and Van Bree L. Species differences in impairment and recovery of alveolar macrophage functions following single and repeated ozone exposures. Toxicol. Appl. Pharmacol. 1101 (1991) 170-178
79. Schlesinger R.B., Fine J.M., and Chen L.C. Interspecies differences in the phagocytic activity of pulmonary macrophages subjected to acidic challenge. Fundam. Appl. Toxicol. 194 (1992) 584-589
80. Krombach F., Munzing S., Allmeling A.M., Gerlach J.T., Behr J., and Dorger M. Cell size of alveolar macrophages: an interspecies comparison. Environ. Health Perspect. 105 Suppl 5 (1997) 1261-1263
81. Bowden D.H. Cell Turnover in the Lung. Am. Rev. Respir. Dis. 1282 (1983) s46-s48
82. Hickey A., and Garcia-Contreras L. Immunological and toxicological implications for short-term studies in animals of pharmaceutical aerosol delivery to the lungs: relevance to humans. Crit. Rev. Ther. Drug Carr. Syst. 184 (2001) 387-431
83. Staufer D. Scaling theory for aerosol deposition in the lungs of different mammals. J. Aerosol Sci. 6 (1975) 223-225
84. McMahon T., Brain J., and LeMott S. Species Difference in Aerosol Deposition. Inhaled Particles. W. Walton vol. IV (1977), Pergamon Press, Oxford 23-33
85. Brain J.D., and Mensah G.A. Comparative toxicology of the respiratory tract. Am. Rev. Respir. Dis. 1282 (1983) s87-s90
86. Huber G., Johanson W., and LaForce F. Experimental models and pulmonary antimicrobial defenses. In: Brain J., Proctor D., and Reid L. (Eds). Respiratory Defense Mechanisms (1977), Marcel Dekker, New York 983-1001
87. Nguyen B., Peterson P., Verbrugh H., Quie P., and Hoidal J. Differences in phagocytosis and killing by alveolar macrophages from humans, rabbits, rats and hamsters. Infect. Immun. 36 (1982) 504-509
88. Dorato M.A. Overview of inhalation toxicology. Environ. Health Perspect. 85 (1990) 163-170
89. Tetsuya O., and Hiroaki O. Nanoparticle-containing microspheres drug delivery system (DDS) for inhalation therapy. J. Aerosol Res. 211 (2006) 10-15
90. Koushik K., Dhanda D.S., Cheruvu N.P., and Kompella U.B. Pulmonary delivery of Deslorelin: large-porous PLGA particles and HPβCD complexes. Pharm. Res. 217 (2004) 1119-1126
91. L. Garcia-Contreras, J. Sung, K. Elbert, A. Hawi, M. Robinson, D. Edwards, A. Hickey, Pharmacokinetics of aerosolized rifampicin large porous particles in the guinea pig in: R.N. Dalby, P.R. Byron, J. Peart, J. Suman, S. Farr, (Eds.), Respiratory Drug Delivery X. Davis Healthcare International Publishing, LCC. River Grove, IL, 3:873-876.
92. Codrons V., Vanderbist F., Ucakar B., Préat V., and Vanbever R. Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone from rat lungs. J. Pharm. Sci. 935 (2004) 1241-1252
93. Minne A., and Vanbever R. Development of an inhalation dry powder and assessment of its pulmonary distribution in mice. J. Aerosol Med. 202 (2007) 164-209
94. Gervelas C., Serandour A.L., Geiger S., Grillon G., Fritsch P., Taulelle C., Le Gall B., Benech H., Deverre J.-R., Fattal E., and Tsapis N. Direct lung delivery of a dry powder formulation of DTPA with improved aerosolization properties: effect on lung and systemic decorporation of plutonium. J. Control. Release 1181 (2007) 78-86
95. Burnell P.K.P., Kidger J., Gascoigne M., and Kotzer C. Powder deposition in rats assessed in vivo and in silico. In: Dalby R.N., Byron P.R., Peart J., Suman J., and Farr S. (Eds). Respiratory Drug Delivery X (2006), Davis Healthcare International Publishing, LCC, River Grove, IL 625-627
96. Suarez S., O'Hara P., Kazantseva M., Newcomer C., Hopfer R., McMurray D., and Hickey A. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J. Antimicrob. Chemother. 48 (2001) 431-434
97. Suarez S., O'Hara P., Kazantseva M., Newcomer C., Hopfer R., McMurray D., and Hickey A. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Screening in an infectious disease model. Pharm. Res. 19 (2001) 1315-1319
98. García-Contreras L., Sethuraman V.V., Kazantseva M., Godfrey V., and Hickey A. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig. J. Antimicrob. Chemother. 58 (2006) 980-986
99. Kuraki T., Ishibashi M., Takayama M., Shiraishi M., and Yoshida M. Human neutrophile elastase using microsprayer induced emphysematous changes in rats. Am. J. Respir. Crit. Care Med. 1613 2 (2000) A872 (Suppl.)
100. Mata J.F., Altes T.A., Cai J., Ruppert K., Mitzner W., Hagspiel K.D., Patel B., Salerno M., Brookerman J.R., deLange E.E., Tobias W.A., Wang H.T., Gates G.D., and Mugler J.P. Evaluation of emphysema severity and progression in a rabbit model: a comparison of hyperpolarized He-3 and Xe-129 diffusion MRI with lung morphometry. J. Appl. Physiol. 102 (2007) 1273-1280
101. Taylor M., Hickey A., and VanOort M. Manufacture, characterization, and pharmacodynamic evaluation of engineered ipratropium bromide particles. Pharm. Dev. Technol. 11 (2007) 321-336
102. Gagnadoux F., Le Pape A., Urban T., Montharu J., Vecellio L., Dubus J., Leblond V., Diot P., Grimbert D., Racineux J., and Lemarie E. Safety of pulmonary administration of gemcitabine in rats. J. Aerosol Med. 182 (2005) 198-206
103. Garcia-Contreras L., Morcol T., Bell S.J.D., and Hickey A.J. Evaluation of novel calcium phosphate particles as pulmonary delivery systems for insulin in rats. AAPS PharmSci 33 (2001)
104. Garcia-Contreras L., Sarubbi D., Flanders E., O'Toole D., Smart J., Newcomer C., and Hickey A.J. Immediate and short-term cellular and biochemical responses to pulmonary single-dose studies of insulin and H-MAP. Pharm. Res. 1812 (2001) 1685-1693
105. Suarez S., García-Contreras L., Sarubbi D., Flanders E., O'Toole D., Smart J., and Hickey A.J. Facilitation of pulmonary insulin absorption by H-MAP: pharmacokinetics and pharmacodynamics in rats. Pharm. Res. 1812 (2001) 1677-1684
106. Takeda K., Miyahara N., Rha Y.-H., Taube C., Yang E.-S., Joetham A., Kodama T., Balhorn A.M., Dakhama A., Duez C., Evans A.J., Voelker D.R., and Gelfand E.W. Surfactant protein D regulates airway function and allergic inflammation through modulation of macrophage function. Am. J. Respir. Crit. Care Med. 168 (2003) 783-789
107. Lu D., Garcia-Contreras L., Xu D., Kurtz S., Liu J., Braunstein M., McMurray D., and Hickey A. Poly (Lactide-co-Glycolide) Microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B. Pharm. Res. 10 (2007) 1834-1843
108. Flotte T.R., and Laube B.L. Gene therapy in cystic fibrosis. Chest 120 (2001) 124S-131S
109. Pettis R., Hall I., Costa D., and Hickey A. Aerosol delivery of muramyl dipeptide to rodent lungs. AAPS PharmSci 23 (2000) (Article 25)
110. García-Contreras L., and Hickey A.J. Pharmacokinetics of aerosolized rifampicin in the guinea pig. In: Dalby R.N., Byron P.R., Peart J., and Farr S. (Eds). Respiratory Drug Delivery vol. VIII (2002), Davis Horwood International Publishing, Ltd., Raleigh, NC
111. Garcia-Contreras L., Fiegel J., Telko M., Elbert K., Hawi A., Thomas M., VerBerkmoes J., Germishuizen W., Fourie P., Hickey A., and Edwards D. Inhaled capreomycin large porous particles for the treatment of tuberculosis in the guinea pig model. Antimicrob. Agents Chemother. 518 (2007) 2830-2836
112. In: Linder J., and Rennard S.I. (Eds). Bronchoalveolar Lavage (1988), ASCP Press, Chicago, IL 179
113. Mauderly J.L. Bronchopulmonary lavage of small laboratory animals. Lab. Anim. Sci. 27 (1977) 255-261
114. Kipnis E. Using urea as an endogenous marker of bronchoalveolar lavage dilution. Crit. Care. Med. 339 (2005) 2153
115. Hsu M.C.-P., and Bai J.P.F. Investigation into the presence of insulin-degrading enzyme in culture type II alveolar cells and the effects of enzyme inhibitors on pulmonary bioavailability of insulin in rats. J. Pharm. Pharmacol. 50 (1998) 507-514
116. Harkness J., and Wagner J.E. The Biology and Medicine of Rabbits and Rodents (1995), Williams & Wilkins, Media, PA
117. Oliver C.E., Craigmill A.L., Caton J.S., Anderson R.C., and Smith D.J. Pharmacokinetics of ruminally dosed sodium [36Cl]chlorate in beef cattle. J. Vet. Pharmacol. Ther. 304 (2007) 358-365
118. Olsen L., Ingvast-Larsson C., Bondesson U., Brostrom H., Tjalve H., and Larsson P. Cetirizine in horses: pharmacokinetics and effect of ivermectin pretreatment. J. Vet. Pharmacol. Ther. 303 (2007) 194-200
119. Borges F.A., Cho H.S., Santos E., Oliveira G.P., and Costa A.J. Pharmacokinetics of a new long acting endectocide formulation containing 2.25% ivermectin and 1.25% abamectin in cattle. J. Vet. Pharmacol. Ther. 301 (2007) 62-67
120. Hubenov H., Bakalov D., Krastev S., Yanev S., Haritova A., and Lashev L. Pharmacokinetic studies on tobramycin in horses. J. Vet. Pharmacol. Ther. 304 (2007) 353-357
121. Marín P., Fernández-Varón E., Escudero E., and Cárceles C.M. Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of difloxacin in sheep. Res. Vet. Sci. 832 (2007) 234-238
122. Shukla M., Singh G., Sindhura B.G., Telang A.G., Rao G.S., and Malik J.K. Comparative plasma pharmacokinetics of meloxicam in sheep and goats following intravenous administration. Comp. Biochem. Physiol., C Toxicol. Pharmacol. 1454 (2007) 528-532
123. Suarez S., and Hickey A.J. Pharmacokinetic and pharmacodynamic aspects of inhaled therapeutic agents. In: Martonen T. (Ed). Medical Applications of Computer Modelling: The Respiratory System. Advances in Computational Bioengineering vol. 4 (2001), WIT Press, Southampton UK 225-304
124. Cuddihy R. Respiratory Tract Retention of Inhaled Particles in Experimental Animals (1976), Inhalation Toxicology Research Institute, Lovelace Foundation, Albuquerque, NM 137-142
125. Bailey M., Kreyling W., Andrea S., Batchelor A., Collier C., Drosselmeyer E., Ferron G., Foster P., Patrick G., Pearman I., Pickering S., Ramsden D., Stirling C., and Talbot R. An interspecies comparison of the lung clearance of inhaled monodisperse cobalt oxide particles - Part I: objectives and summary of results. J. Aerosol Sci. 202 (1989) 169-188
126. R. Cuddihy, Mathematical models for predicting clearance of inhaled radioactive substances. Lung modeling for inhalation of radioactive materials. H. Smith, G. Gerber. Report EUR 9384, Commission of the European Communities, 1984, 167-179.
127. Kreyling W., Ferron G., Schumann G., and Heilmann P. Macrophage mediated particle transport from the lungs. J. Aerosol Med. 3 (1990) 285
128. Chandra T., Miller I.F., and Yeates D.B. A pore transport model for pulmonary alveolar epithelium. Ann. Biomed. Eng. 20 (1992) 481-494
129. A.R. Clark, M. Egan, Modelling the deposition of inhaled powder drug aerosols, 25 (1994) 175-186.
130. Gumbleton M. Caveolae as potential macromolecule trafficking compartments within alveolar epithelium. Adv. Drug Deliv. Rev. 493 (2001) 281-300
131. Gumbleton M., Hollins A.J., Omidi Y., Campbell L., and Taylor G. Targeting caveolae for vesicular drug transport. J. Control. Rel. 87 (2003) 139-151
132. Byron P.R. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J. Pharm. Sci. 755 (1986) 433-438
133. Gonda I. Drugs administered directly into the respiratory tract: modeling of the duration of effective drug levels. J. Pharm. Sci. 774 (1988) 340-346
134. In: Gibaldi M., and Perrier D. (Eds). Pharmacokinetics (1982), Marcel Dekker, New York
135. Adjei A., Qiu Y., and Gupta P. Bioavailability and pharmacokinetics of inhaled drugs. In: Hickey A.J. (Ed). Inhalation Aerosols. Physical and Biological Basis for Therapy (1996), Marcel Dekker, New York 197-232
136. Gabrielsson J., and Weiner D. Pharmacokinetic and Pharmacokinetic Data Analysis: Concepts and Applications (2000), Swedish Pharmaceutical Press, Stockholm, Sweden
137. Chowhan Z., and Amaro A. Pulmonary absorption studies utilizing in situ rat lung model: designing dosage regimen for bronchial delivery of new drug entities. J. Pharm. Sci. 6511 (1976) 1669-1672
138. Wagner J. "Absorption rate constants" calculated according to one-compartment open model with first-order absorption: implications for the in-vivo in-vitro correlations. J. Pharm. Sci. 59 (1970) 1049
139. Loo J., and Riegelman S. New method for calculatin the intrinsec absorption rate of drugs. J. Pharm. Sci. 57 (1968) 918-928
140. Le Brun P.P., Vinks A., Touw D., Hekelaar N., Mannes G., Brimicombe R.W., Frijlink E.H., and Heijerman H. Can tobramycin inhalation be improved with a jet nebulizer?. Ther. Drug Monit. 216 (1999) 619
141. Schanker L., Mitchel E., and Brown R. Species comparison of drug absorption from the lung after inhalation or intratracheal injection. Drug Metab. Dispos. 14 (1986) 79-88
142. Hindle M., and Chrystyn H. Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br. J. Clin. Pharmacol. 34 (1992) 311-315
143. Pedersen S., Steffensen G., Ekman I., Tonnesson M., and Borga O. Bioavailability of inhaled budesonide in children with asthma. Eur. J. Clin. Pharmacol. 31 (1987) 579-582
144. Mollmann H., Wagner M., Meibohm B., Hochhaus G., Barth J., Stockmann R., Krieg M., Weisser H., Falcoz C., and Derendorf H. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur. J. Clin. Pharmacol. 53 (1998) 459-467
145. Patton J.S., Bukar J., and Nagarajan S. Inhaled insulin. Adv. Drug Deliv. Rev. 35 (1999) 235-247
146. Niven R.W., Whitcomb K.L., Woodward M., Liu J., and Jornacion C. Systemic absorption and activity of recombinant consensus interferon and after intratracheal instillation and aerosol administration. Pharm. Res. 12 (1995) 1889-1895
147. Colthorpe P., Farr S., Taylor G., Smith D.J., and Wyatt D. The pharmacokinetics of pulmonary deliverd insulin: a comparison of intratracheal and aerosol administration to the rabbit. Pharm. Res. 9 (1992) 764-768
148. Pillai R.S., Hughes B.L., Wolff R.K., Heisserman J.A., and Dorato M.A. The effect of pulmonary delivered insulin on blood glucose levels using two nebulizers. J. Aerosol Med. 9 (1996) 227-240
149. Berridge M.S., and Heald D.L. In vivo characterization of inhaled pharmaceuticals using quantitative positron emission tomography. J. Clin. Pharmacol. (1999) 25S-29S (Suppl)
150. Berridge M.S., Lee Z., and Heald D.L. Regional distribution and kinetics of inhaled pharmaceuticals. Curr. Pharm. Des. 616 (2000) 1631-1651
151. Kreyling W.G., Blanchard J.D., Godleski J.J., Haeussermann S., Heyder J., Hutzler P., Schulz H., Sweeney T.D., Takenaka S., and Ziesenis A. Anatomic localization of 24- and 96-h particle retention in canine airways. J. Appl. Physiol. 871 (1999) 269-284
152. Ntziachristos V., Ripoll J., Wang L.V., and Weissleder R. Looking and listening to light: the evolution of whole-body photonic imaging. Nat. Biotechnol. 233 (2005) 313-320
153. Gagnadoux F., Le Pape A., Urban T., Montharu J., Vecellio L., Dubus J.C., Leblond V., Diot P., Grimbert D., Racineux J.L., and Lemarie E. Safety of pulmonary administration of gemcitabine in rats. J. Aerosol Med. 182 (2005) 198-206
154. Khanna C., Waldrep J.C., Anderson P.M., Weischelbaum R.W., Hasz D.E., Katsanis E., and Klausner J.S. Nebulized interleukin 2 liposomes: aerosol characteristics and biodistribution. J. Pharm. Pharmacol. 4910 (1997) 960-971
155. Lerondel S., Le Pape A., Sene C., Faure L., Bernard S., Diot P., Nicolis E., Mehtali M., Lusky M., Cabrini G., and Pavirani A. Radioisotopic imaging allows optimization of adenovirus lung deposition for cystic fibrosis gene therapy. Hum. Gene Ther. 121 (2001) 1-11
156. Lerondel S., Vecellio None L., Faure L., Sizaret P.Y., Sene C., Pavirani A., Diot P., and Le Pape A. Gene therapy for cystic fibrosis with aerosolized adenovirus-CFTR: characterization of the aerosol and scintigraphic determination of lung deposition in baboons. J. Aerosol Med. 141 (2001) 95-105
157. Deshpande D.S., Blanchard J.D., Schuster J., Fairbanks D., Hobbs C., Beihn R., Densmore C., Farr S., and Gonda I. Gamma scintigraphic evaluation of a miniaturized AERx pulmonary delivery system for aerosol delivery to anesthetized animals using a positive pressure ventilation system. J. Aerosol Med. 181 (2005) 34-44
158. Gagnadoux F., Leblond V., Vecellio L., Hureaux J., Le Pape A., Boisdron-Celle M., Montharu J., Majoral C., Fournier J., Urban T., Diot P., Racineux J.L., and Lemarie E. Gemcitabine aerosol: in vitro antitumor activity and deposition imaging for preclinical safety assessment in baboons. Cancer Chemother. Pharmacol. 582 (2006) 237-244
159. Rhodes C.G., and Hughes J.M. Pulmonary studies using positron emission tomography. Eur. Respir. J. 86 (1995) 1001-1017
160. Dolovich M., and Labiris R. Imaging drug delivery and drug responses in the lung. Proc. Am. Thorac. Soc. 14 (2004) 329-337
161. Rao J., Dragulescu-Andrasi A., and Yao H. Fluorescence imaging in vivo: recent advances. Curr. Opin. Biotechnol. 181 (2007) 17-25
162. Contag P.R. Whole-animal cellular and molecular imaging to accelerate drug development. Drug Discov. Today 710 (2002) 555-562
163. DeGeorge J.J., Ahn C.H., Andrews P.A., Brower M.E., Choi Y.S., Chun M.Y., Du T., Lee-Ham D.Y., McGuinn W.D., Pei L., Sancilio L.F., Schmidt W., Sheevers H.V., Sun C.J., Tripathi S., Vogel W.M., Whitehurst V., Williams S., and Taylor A.S. Considerations for toxicology studies of respiratory drug products. Regul. Toxicol. Pharmacol. 252 (1997) 189-193
164. A. Dahl, Metabolic characteristics of the respiratory tract. Concepts in inhalation toxicology. H.R. McClellan RO. New York, Hemisphere (1989) 141-160.
165. Pauluhn J., and Mohr U. Inhalation studies in laboratory animals-current concepts and alternatives. Toxicol. Pathol. 285 (2000) 734-753
166. Boyd M.R., and Neal R.A. Studies on the mechanism of toxicity and of development of tolerance to the pulmonary toxin, alpha-naphthylthiourea (ANTU). Drug Metab. Dispos. 44 (1976) 314-322
167. Pauluhn J. Overview of testing methods used in inhalation toxicity: from facts to artifacts. Toxicol. Lett. 140-141 (2003) 183-193
168. Pauluhn J. Issues of dosimetry in inhalation toxicity. Toxicol. Lett. 140-141 (2003) 229-238
169. Y.-S. Cheng, O. Moss, Inhalation exposure systems. Concepts in Inhalation Toxicology. H. R. McClellan RO. New York, Hemisphere Publishing Corporation (1989) 19-56.
170. Kennedy G. Inhalation toxicology. In: Hayes W. (Ed). Principles and Methods. Toxicology (1989), Raven Press, New York 361-382
171. Phalen R.F. Methods in Inhalation Toxicology (1997), CRC Press, Boca Raton 156
172. Hoymann H.G. Invasive and noninvasive lung function measurements in rodents. J. Pharmacol. Toxicol. Methods 551 (2007) 16-26
173. Alexander D.J., and Libretto S.E. An overview of the toxicology of HFA-134a (1,1,1,2-tetrafluoroethane). Hum. Exp. Toxicol. 149 (1995) 715-720
174. Alexander D.J., Libretto S.E., Chevalier H.J., Imamura T., Pappritz G., and Wilson J. HFA-134a (1,1,1,2-tetrafluoroethane); lack of oncogenicity in rodents after inhalation. Hum. Exp. Toxicol. 149 (1995) 706-714
175. Alexander D.J., Libretto S.E., Adams M.J., Hughes E.W., and Bannerman M. HFA-134a (1,1,1,2-tetrafluoroethane): effects of inhalation exposure upon reproductive performance, development and maturation of rats,. Hum.
176. Mercier E., Valat C., Fishman R.S., Fink J.B., Smith N., Gibbons K., Diot P., and Dequin P.-F. Aerosol Delivery of Amikacin by Three Nebulizers of Varying Efficiency in Patients on Mechanical Ventilators (2004), American Thoracic Society International Conference
177. Marra F., Partovi N., Wasan K.M., Kwong E.H., Ensom M.H., Cassidy S.M., Fradet G., and Levy R.D. Amphotericin B disposition after aerosol inhalation in lung transplant recipients. Ann. Pharmacother. 361 (2002) 46-51
178. Grp V. Inhaled apomorphine [VR004] improves erectile dysfunction with a rapid onset of action. Inpharma Weekly 1397 (2003) 13
179. Dunbar J., Illeperuma A., Milovanovic J., Loewy J., Osborn C., Ahluwalia P., Richards J., and Ehrich E.W. A Placebo-And Active-Comparator Controlled Dose Escalation Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Inhaled Large Porous Particle AIR Epinephrine in Normal Volunteers (2004), American Academy of Allergy, Asthma and Immunology (AAAAI), San Francisco
180. Mather L.E., Woodhouse A., Ward M.E., Farr S.J., Rubsamen R.A., and Eltherington L.G. Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery. Br. J. Clin. Pharmacol. 461 (1998) 37-43
181. Sablotzki A., Hentschel T., Hofmann S., Simm A., Muhling J., and Czeslick E. Inhaled aerosolized iloprost in the evaluation of heart transplant candidates-experiences with 45 cases. J. Clin. Anesth. 182 (2006) 108-113
182. Puikuan K., Chunyu Z., Jin F., Chaoshu T., and Junbao D. Inhalation of nebulized nitroglycerin, a nitric oxide donor, for the treatment of pulmonary hypertension induced by high pulmonary blood flow. Heart Vessels 213 (2006) 169-179
183. Lam C.F., van Heerden P.V., Ilett K.F., Caterina P., and Filion P. Two aerosolized nitric oxide adducts as selective pulmonary vasodilators for acute pulmonary hypertension. Chest 1233 (2003) 869-874
184. Adams R., Christenson J., Petersen F., and Beatty P. Pre-emptive use of aerosolized ribavirin in the treatment of asymptomatic pediatric marrow transplant patients testing positive for RSV. Bone Marrow Transplant. 246 (1999) 661-664
185. R.L. Hale, J.D. Rabinowitz, D.W. Solas, A.C. Zaffaron, Patent number: US7005122 (2006). Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route.
186. Solvay P. Data Show New Synthetic D-9-THC Inhaler Offers Safe, Rapid Delivery (2005). http://www.solvaypharmaceuticalsus.com from http://www.solvaypharmaceuticalsus.com
187. Casella J. Novel inhalation technology delivers intravenous-like pharmacokinetics of prochlorperazine in healthy volunteers. Headache 45 (2005) S96
188. Voswinckel R., Ghofrani H.A., Grimminger F., Seeger W., and Olschewski H. Inhaled treprostinil [corrected] for treatment of chronic pulmonary arterial hypertension. Ann. Intern. Med. 1442 (2006) 149-150
189. Patton J.S., Bukar J.G., and Eldon M.A. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin. Pharmacokinet. 4312 (2004) 781-801
190. Lizio R., Klenner T., Borchard G., Romeis P., Sarlikiotis A.W., Reissmann T., and Lehr C.M. Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. Eur. J. Pharm. Sci. 93 (2000) 253-258
191. Iacono A.T., Johnson B.A., Grgurich W.F., Youssef J.G., Corcoran T.E., Seiler D.A., Dauber J.H., Smaldone G.C., Zeevi A., Yousem S.A., Fung J.J., Burckart G.J., McCurry K.R., and Griffith B.P. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N. Engl. J. Med. 3542 (2006) 141-150
192. Low S.C., Nunes S.L., Bitonti A.J., and Dumont J.A. Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum. Reprod. 207 (2005) 1805-1813
193. Codrons V., Vanderbist F., Ucakar B., Preat V., and Vanbever R. Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1-34) from rat lungs. J. Pharm. Sci. 935 (2004) 1241-1252
194. Qi Y., Zhao G., Liu D., Shriver Z., Sundaram M., Sengupta S., Venkataraman G., Langer R., and Sasisekharan R. Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route. Proc. Natl. Acad. Sci. U. S. A. 10126 (2004) 9867-9872
195. Kobayashi S., Kondo S., and Juni K. Study on pulmonary delivery of salmon calcitonin in rats: effects of protease inhibitors and absorption enhancers. Pharm. Res. 119 (1994) 1239-1243
196. Tazawa R., Nakata K., Inoue Y., and Nukiwa T. Granulocyte-macrophage colony-stimulating factor inhalation therapy for patients with idiopathic pulmonary alveolar proteinosis: a pilot study; and long-term treatment with aerosolized granulocyte-macrophage colony-stimulating factor: a case report. Respirology 11 (2006) S61-S64 (Suppl)
197. T. Nilsson, S. Calander, A. Niemi, C. Friberg, L. Kax, M. Myrman, Patent number: WO/2006/059939 (2006), Medical product for inhalation containing glucagon-like peptide-1 (GLP-1).
198. Russell M.S.R.K.E., Bellinger D.A., Leitermann K., Rup B.J., McCarthy K.P., Keith J.J.C., Khor S.P., Schaub R.G., and Nichols T.C. Intratracheal administration of recombinant human factor IX (BeneFix™) achieves therapeutic levels in hemophilia B dogs. Thromb. Haemost. 85 (2001) 445-449
199. Bot A.I., Tarara T.E., Smith D.J., Bot S.R., Woods C.M., and Weers J.G. Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm. Res. 173 (2000) 275-283
200. Martin P.L., Vaidyanathan S., Lane J., Rogge M., Gillette N., Niggemann B., and Green J. Safety and systemic absorption of pulmonary delivered human IFN-beta1a in the nonhuman primate: comparison with subcutaneous dosing. J. Interferon Cytokine Res. 226 (2002) 709-717
201. Shahiwala A., and Misra A. A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: a technical note. AAPS PharmSciTech 63 (2005) E482-E486
202. Leach C.L., Kuo M.C., Bueche B., Fishburn S., Viegas T., Bossard M., Guo L., Bentley M.D., Hobbs C.H., Cherrington A.D., and Patton J.S. Modifying the pulmonary absorption and retention of proteins through PEGylation. In: Dalby R., Byron P., and Farr S. (Eds). Respir. Drug Deliv. vol. IX (2004) 69-78
203. Hussain A., Arnold J.J., Khan M.A., and Ahsan F. Absorption enhancers in pulmonary protein delivery. J. Control. Release 941 (2004) 15-24
204. Koushik K., Dhanda D.S., Cheruvu N.P., and Kompella U.B. Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes. Pharm. Res. 217 (2004) 1119-1126
205. Mahesh Kumar T., and Misra A. Pulmonary absorption enhancement of salmon calcitonin. J. Drug Target. 123 (2004) 135-144
206. Hussain A., Majumder Q.H., and Ahsan F. Inhaled insulin is better absorbed when administered as a dry powder compared to solution in the presence or absence of alkylglycosides. Pharm. Res. 231 (2005) 138-147
207. Yamada K., Odomi M., Okada N., Fujita T., and Yamamoto A. Chitosan oligomers as potential and safe absorption enhancers for improving the pulmonary absorption of interferon-alpha in rats. J. Pharm. Sci. 9411 (2005) 2432-2440
208. Li L., Mathias N.R., Heran C.L., Moench P., Wall D.A., and Smith R.L. Carbopol-mediated paracellular transport enhancement in Calu-3 cell layers. J. Pharm. Sci. 952 (2006) 326-335
209. Saso Y., Seki T., Fukuchi R., Chono S., and Morimoto K. Effect of lecithin coating on the pulmonary absorption of furosemide in rats. Biol. Pharm. Bull. 297 (2006) 1445-1448
210. Evora C., Soriano I., Rogers R.A., Shakesheff K.N., Hanes J., and Langer R. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. J. Control. Release 512-513 (1998) 143-152
211. Morimoto K., Katsumata H., Yabuta T., Iwanaga K., Kakemi M., Tabata Y., and Ikada Y. Gelatin microspheres as a pulmonary delivery system: evaluation of salmon calcitonin absorption. J. Pharm. Pharmacol. 526 (2000) 611-617
212. Steiner S., Pfutzner A., Wilson B.R., Harzer O., Heinemann L., and Rave K. Technosphere/insulin-proof of concept study with a new insulin formulation for pulmonary delivery. Exp. Clin. Endocrinol. Diabetes 1101 (2002) 17-21
213. Surendrakumar K., Martyn G.P., Hodgers E.C., Jansen M., and Blair J.A. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J. Control. Release 913 (2003) 385-394
214. Dumont J.A., Bitonti A.J., Clark D., Evans S., Pickford M., and Newman S.P. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J. Aerosol Med. 183 (2005) 294-303
215. Bitonti A.J., and Dumont J.A. Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Adv. Drug Deliv. Rev. 589-610 (2006) 1106-1118
216. V.W. Chaffee, Surgery of laboratory animals. Handbook of Laboratory Animal Science. E.C. Melby Jr., N.H. Altman. CRC Press. I, Cleveland, OH, (1974) 233-273.